LY011
/ China Biotech Services, Longyao Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 19, 2021
Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
CAR T-Cell Therapy • Clinical • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18
July 26, 2021
A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Shanghai Longyao Biotechnology Inc., Ltd.
New P1 trial • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18
1 to 2
Of
2
Go to page
1